A randomized controlled trial for the traditional Chinese medicine Jinhong Decoction in the prevention and treatment of sepsis based on truncation and torsion strategy

注册号:

Registration number:

ITMCTR1900002275

最近更新日期:

Date of Last Refreshed on:

2019-04-11

注册时间:

Date of Registration:

2019-04-11

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于“截断扭转”策略的中医药锦红汤内服治疗脓毒症的随机对照试验

Public title:

A randomized controlled trial for the traditional Chinese medicine Jinhong Decoction in the prevention and treatment of sepsis based on truncation and torsion strategy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

锦红汤内服治疗脓毒症的随机对照试验

Scientific title:

A randomized controlled trial for Jinhong Decoction in the treatment of sepsis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900022430 ; ChiMCTR1900002275

申请注册联系人:

张文

研究负责人:

方邦江

Applicant:

Wen Zhang

Study leader:

BangJiang Fang

申请注册联系人电话:

Applicant telephone:

+86 13167062357

研究负责人电话:

Study leader's telephone:

+86 18917763257

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

441993375@qq.com

研究负责人电子邮件:

Study leader's E-mail:

fangbji@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区宛平南路725号

研究负责人通讯地址:

上海市徐汇区宛平南路725号

Applicant address:

725 Wanping Road South, Xuhui District, Shanghai, China

Study leader's address:

725 Wanping Road South, Xuhui District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海中医药大学附属龙华医院

Applicant's institution:

LongHua Hospital Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2019LCSY012

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

上海中医药大学附属龙华医院医学伦理委员会

Name of the ethic committee:

Ethic Committee of LongHua Hospital Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2019/3/28 0:00:00

伦理委员会联系人:

刘胜

Contact Name of the ethic committee:

Sheng Liu

伦理委员会联系地址:

上海市徐汇区宛平南路725号

Contact Address of the ethic committee:

725 Wanping Road South, Xuhui District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属龙华医院

Primary sponsor:

LongHua Hospital Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市徐汇区宛平南路725号

Primary sponsor's address:

725 Wanping Road South, Xuhui District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属龙华医院

具体地址:

上海市徐汇区宛平南路725号

Institution
hospital:

LongHua Hospital Shanghai University of Traditional Chinese Medicine

Address:

725 Wanping Road South, Xuhui District, Shanghai, China

经费或物资来源:

国家重点研发计划

Source(s) of funding:

The National Key Research and Development Program of China

研究疾病:

脓毒症

研究疾病代码:

Target disease:

Sepsis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

采用多中心、随机、双盲、对照研究,评价锦红汤内服对脓毒症病原体清除力、内环境稳态修复能力、器官功能及预后影响。

Objectives of Study:

A multicenter, randomized, double-blind, controlled study was performed to evaluate the effects of jinhong decoction on regulating pathogen clearance, homeostasis, organ function and prognosis in patients with sepsis.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)发病年龄在18岁到80岁之间; 2)符合2016年国际严重脓毒症及脓毒症休克指南诊断标准; 3)APACHE II评分<30; 4)自愿参加本次试验并签署知情同意书。

Inclusion criteria

1) Aged 18 and 80 years; 2) Consistent with diagnostic criteria of International Guidelines for Management of Sepsis and Septic Shock: 2016; 3) APACHE II score<30; 4) To be able to and willing to provide signed informed consent.

排除标准:

1)对本项目中药过敏及过敏体质患者; 2)合并有恶性肿瘤、肝硬化、慢性肾功能衰竭(尿毒症期)、血液系统疾病、 HIV 等严重基础疾病患者; 3)长期使用激素、免疫抑制剂等药物治疗的患者; 4)罹患有严重的精神疾病或不能配合本次试验者; 5)同时参加或 30 天内参加过其他临床试验者; 6)妊娠、哺乳期妇女。

Exclusion criteria:

1) Allergy to traditional Chinese medicine or allergy constitution; 2) Severe primary disease including malignant tumor, severe liver and kidney dysfunction, blood diseases and Human Immunodeficiency Virus (HIV); 3) Using hormones or immunosuppressants for a long time; 4) Suffer from severe mental illness or unable to participate in the trial; 5) Participating in other clinical trials in the previous 30 days; 6) Pregnant and lactating women.

研究实施时间:

Study execute time:

From 2019-04-20

To      2021-12-31

征募观察对象时间:

Recruiting time:

From 2019-04-20

To      2021-12-31

干预措施:

Interventions:

组别:

试验组

样本量:

760

Group:

experimental group

Sample size:

干预措施:

锦红汤+西医基础及对因治疗

干预措施代码:

Intervention:

Jinhong Decoction combined with basic and etiotropic therapy of western medicine

Intervention code:

组别:

安慰剂对照组

样本量:

760

Group:

Control group

Sample size:

干预措施:

安慰剂+西医基础及对因治疗

干预措施代码:

Intervention:

Placebo combined with basic and etiotropic therapy of western medicine

Intervention code:

样本总量 Total sample size : 1520

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第一附属医院

单位级别:

三级甲等

Institution/hospital:

The First Affiliated Hospital of Guangdong University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

中国人民解放军第三军医大学

单位级别:

三级甲等

Institution/hospital:

Third Military Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院西苑医院

单位级别:

三级甲等

Institution/hospital:

Xiyuan Hospital, China Academy of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院

单位级别:

三级甲等

Institution/hospital:

Dongzhimen Hospital of Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海长海医院

单位级别:

三级甲等

Institution/hospital:

Changhai Hospital of Shanghai

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西

市(区县):

西安

Country:

China

Province:

Shaanxi

City:

Xi'an

单位(医院):

西安交通大学第二附属医院

单位级别:

三级甲等医院

Institution/hospital:

The Second Affiliated Hospital of Xi’an Jiaotong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属龙华医院

单位级别:

三级甲等

Institution/hospital:

LongHua Hospital Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院

单位级别:

三级甲等

Institution/hospital:

Huashan Hospital of Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

28 天、60 天病死率

指标类型:

主要指标

Outcome:

28-days and 60-days Deaths

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

炎症指标

指标类型:

次要指标

Outcome:

inflammatory biomarkers

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主要器官功能

指标类型:

次要指标

Outcome:

major organ function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

氧化应激指标

指标类型:

次要指标

Outcome:

the marker of oxidative stress

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医症候积分

指标类型:

次要指标

Outcome:

traditional Chinese medicine Syndrome Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SOFA 评分

指标类型:

次要指标

Outcome:

SOFA score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道菌群变化

指标类型:

次要指标

Outcome:

the changes of intestinal flora

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生命体征

指标类型:

次要指标

Outcome:

vital signs

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间、费用

指标类型:

次要指标

Outcome:

hospital costs and hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

stools

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由第三方统计人员经统计软件生成随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number generated by the statistical software from third-party statisticians

盲法:

双盲

Blinding:

Doble blind method for investgators and patients

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Chinese Clinical Trial Registry

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

eCRF and EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

eCRF and EDC

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above